Crinetics Pharmaceuticals (CRNX) Total Current Liabilities (2017 - 2026)

Crinetics Pharmaceuticals' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $71.1 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 24.04% year-over-year to $71.1 million; the TTM figure through Mar 2026 stood at $71.1 million (up 24.04% YoY), while the FY2025 annual figure was $85.1 million, up 42.54% from the prior year.
• Total Current Liabilities was $71.1 million for Q1 2026 at Crinetics Pharmaceuticals, down from $85.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $85.1 million in Q4 2025 to a low of $20.3 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $48.1 million across 5 years, with a median of $51.8 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 119.1% in 2022, then advanced 10.71% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $27.7 million in 2022, then jumped by 58.5% to $43.9 million in 2023, then soared by 35.82% to $59.7 million in 2024, then jumped by 42.54% to $85.1 million in 2025, then decreased by 16.44% to $71.1 million in 2026.
• The last three Total Current Liabilities figures came in at $71.1 million (Q1 2026), $85.1 million (Q4 2025), and $74.2 million (Q3 2025), per Business Quant data.